Cargando…
Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer
A kinesin family member 5b (KIF5B)-MET proto-oncogene, receptor tyrosine kinase (MET) rearrangement was reported in patients with lung adenocarcinoma but its oncogenic function was not fully evaluated. We used one-step reverse transcription-polymerase chain reaction for RNA samples to screen for the...
Autores principales: | Gow, Chien-Hung, Liu, Yi-Nan, Li, Huei-Ying, Hsieh, Min-Shu, Chang, Shih-Han, Luo, Sheng-Ching, Tsai, Tzu-Hsiu, Chen, Pei-Lung, Tsai, Meng-Feng, Shih, Jin-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068088/ https://www.ncbi.nlm.nih.gov/pubmed/30015159 http://dx.doi.org/10.1016/j.neo.2018.06.007 |
Ejemplares similares
-
MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis
por: Tsai, Tzu‐Hsiu, et al.
Publicado: (2023) -
Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
por: Gow, Chien-Hung, et al.
Publicado: (2023) -
miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
por: Liu, Yi-Nan, et al.
Publicado: (2020) -
Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report
por: Wu, Zhi-Wei, et al.
Publicado: (2021) -
Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
por: Lin, Chien-Yu, et al.
Publicado: (2022)